Investigational drug · Phase 2
SPC5004
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SPC5004"
First trial start
2024
Dec 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPC5004", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertension (HTN)
- NYHA Class III Heart Failure
- NYHA Class IV Heart Failure
- Diabete Mellitus
Approved drugs for the same conditions: High blood pressure (hypertension) · Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SPC5004" as an intervention, largest first.
- Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential HypertensionPivotal-lookingEnrolling by invitation
Shin Poong Pharmaceutical Co. Ltd.Industry
NCT07064525 · 252 participants (planned) · Start Dec 5, 2024 · Primary completion Dec 15, 2025
Drug: SPC1001 Low; SPC5002 and 2 more · For: Hypertension (HTN); NYHA Class III Heart Failure; NYHA Class IV Heart Failure and 1 more
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hypertension (HTN)
- QCZ484Phase 23 trials
Novartis · Hypertension (HTN), Hypertension, Hypercholesterolaemia
- of QLS1410Phase 22 trials
Qilu Pharmaceutical Co., Ltd. · Hypertension (HTN), Uncontrolled Hypertension
- SPC1001Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure
- SPC5002Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure
- SPC5003Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.